
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Chemo France
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
Details : Drospirenone is a Hormone drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contraception.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 21, 2014
Lead Product(s) : Drospirenone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Chemo France
Deal Size : Inapplicable
Deal Type : Inapplicable

Contact Us!